Skip to main content
. Author manuscript; available in PMC: 2011 May 1.
Published in final edited form as: Cancer Res. 2010 Oct 8;70(22):9003–9011. doi: 10.1158/0008-5472.CAN-10-2364

Figure 2.

Figure 2

Relationship between dose of resveratrol and maximal plasma concentration (Cmax) (A) or area under the plasma concentration versus time curve (AUClast) (B) for resveratrol (black, rhombi), resveratrol-4′-O-glucuronide (red, squares), resveratrol-3-O-glucuronide (green, triangles) and resveratrol-3-O-sulfate (blue, crosses) in healthy volunteers, after a dose of resveratrol at either 0.5, 1, 2.5 or 5g ingested on between day 21 and 28 of daily dosing. Values are the mean of 10 volunteers for each dose level. The range of coefficients of variation (as % of the mean) for individual data points is shown in brackets.